For research use only. Not for therapeutic Use.
Sevasemten is an allosteric inhibitor of skeletal muscle myosin. Sevasemten exhibits selectively myosin inhibition with IC50s of ≤10 μM (skeletal), >100 μM (cardiac), respectively[1][2].
| Catalog Number | I041963 |
| CAS Number | 2417395-15-2 |
| Synonyms | 2-[(5-fluoropyridin-3-yl)methyl]-6-[2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl]pyridazin-3-one |
| Molecular Formula | C16H11F4N5O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H11F4N5O2/c17-12-3-10(4-21-7-12)8-25-14(26)2-1-13(24-25)11-5-22-15(23-6-11)27-9-16(18,19)20/h1-7H,8-9H2 |
| InChIKey | XFPJKQRXBAFXNK-UHFFFAOYSA-N |
| SMILES | C1=CC(=O)N(N=C1C2=CN=C(N=C2)OCC(F)(F)F)CC3=CC(=CN=C3)F |
| Reference | [1]. Russell Alan, et al. Preparation of substituted pyridazinones for use in the treatment of neuromuscular diseases: World Intellectual Property Organization, WO2021231615. 2021-11-18. [2]. WHO Drug Information-World Health Organization (WHO). |
